Patents by Inventor Thomas Jon Seiders

Thomas Jon Seiders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190330146
    Abstract: This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 31, 2019
    Applicant: ORION OPHTHALMOLOGY LLC
    Inventors: Austin Chih-Yu Chen, Robert Gomez, Renata Marcella Oballa, David Andrew Powell, Jeffrey Roger Roppe, Thomas Jon Seiders, Tao Sheng
  • Publication number: 20190194140
    Abstract: The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Thomas Jon Seiders, Catherine Yuling Lee, Yiwei Li
  • Patent number: 10301266
    Abstract: The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 28, 2019
    Assignee: Inception 3, Inc.
    Inventors: Thomas Jon Seiders, Catherine Yuling Lee, Yiwei Li
  • Publication number: 20180273483
    Abstract: The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.
    Type: Application
    Filed: April 10, 2018
    Publication date: September 27, 2018
    Inventors: Thomas Jon Seiders, Catherine Yuling Lee, Yiwei Li
  • Patent number: 10000456
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: June 19, 2018
    Assignee: AMIRA PHARMACEUTICALS, INC.
    Inventors: Ryan Clark, Brian Andrew Stearns, Lucy Zhao, Thomas Jon Seiders, Deborah Volkots, Jeannie M. Arruda
  • Patent number: 9987381
    Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of LPA1 receptors in mammals.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: June 5, 2018
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, YALE UNIVERSITY
    Inventors: Thomas Jon Seiders, David J. Donnelly, Samuel J. Bonacorsi, Jr., Kai Cao, Tritin Tran, Adrienne Pena, Joonyoung Kim, Richard E. Carson, Nabeel Nabulsi, Jean-Dominique Gallezot, Yiyun Huang, Jeffrey Roger Roppe
  • Publication number: 20170121295
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Application
    Filed: December 16, 2016
    Publication date: May 4, 2017
    Applicants: AMIRA PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jason Edward BRITTAIN, Thomas Jon SEIDERS, Christopher David KING, Victor W. ROSSO
  • Patent number: 9556133
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: January 31, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, AMIRA PHARMACEUTICALS, INC.
    Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
  • Publication number: 20160256577
    Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of LPA1 receptors in mammals.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 8, 2016
    Inventors: Thomas Jon Seiders, David J. Donnelly, Samuel J. Bonacorsi, JR., Kai Cao, Tritin Tran, Adrienne Pena, Joonyoung Kim, Richard E. Carson, Nabel Nabulsi, Jean-Dominique Gallezot, Yiyun Huang, Jeffrey Roger Roppe
  • Patent number: 9272990
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: March 1, 2016
    Assignee: AMIRA PHARMACEUTICALS, INC.
    Inventors: Thomas Jon Seiders, Bowei Wang, John Howard Hutchinson, Nicholas Simon Stock, Deborah Volkots
  • Publication number: 20140256744
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 11, 2014
    Inventors: Ryan Clark, Brian Andrew Stearns, Lucy Zhao, Thomas Jon Seiders, Deborah Volkots, Jeannie M. Arruda
  • Patent number: 8785393
    Abstract: Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP2 receptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: July 22, 2014
    Assignee: Panmira Pharmaceuticals, LLC
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Nicholas Simon Stock
  • Patent number: 8778983
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: July 15, 2014
    Assignee: Amira Pharmaceuticals, Inc.
    Inventors: Ryan Clark, Brian Andrew Stearns, Lucy Zhao, Thomas Jon Seiders, Deborah Volkots, Jeannie M. Arruda, David Nathan Zalatan
  • Publication number: 20130253023
    Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.
    Type: Application
    Filed: December 7, 2011
    Publication date: September 26, 2013
    Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
  • Publication number: 20130253004
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Application
    Filed: December 6, 2011
    Publication date: September 26, 2013
    Applicant: Amira Pharmaceuticals, Inc.
    Inventors: Thomas Jon Seiders, Bowei Wang, John Howard Hutchinson, Nicholas Simon Stock, Deborah Volkots
  • Publication number: 20130253019
    Abstract: Described herein is the use of LPA1 antagonists in the treatment or prevention of diseases or conditions of the eye of a mammal. Also described are pharmaceutical compositions that include at least one LPA1 antagonist.
    Type: Application
    Filed: June 13, 2011
    Publication date: September 26, 2013
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, James Stephen Swaney
  • Patent number: 8541587
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: September 24, 2013
    Assignee: Amira Pharmaceuticals, Inc.
    Inventors: Thomas Jon Seiders, Jeffrey Roger Roppe, Timothy Andrew Parr
  • Patent number: 8524748
    Abstract: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: September 3, 2013
    Assignee: Panmira Pharmaceuticals, LLC
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Jeannie M. Arruda, Jeffrey Roger Roppe
  • Patent number: 8455499
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: June 4, 2013
    Assignee: Amira Pharmaceuticals, Inc.
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Jeannie M. Arruda
  • Patent number: 8440707
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: May 14, 2013
    Assignee: Amira Pharmaceuticals, Inc.
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Bowei Wang, Jeannie M. Arruda, Jeffrey Roger Roppe, Timothy Parr